News >

Expert Addresses Oncology Costs, Potential Impact of Biosimilars

Brandon Scalea
Published: Wednesday, Sep 19, 2018

Lee S. Rosen, MD, FACP

Lee S. Rosen, MD, FACP
Although bevacizumab (Avastin) has significantly improved outcomes for patients with metastatic colorectal cancer (mCRC), there is limited access to this therapy in some cases, according to Lee S. Rosen, MD, FACP. Additionally, its cost makes it challenging to have a widespread impact—but more bevacizumab biosimilars could have an effect, he said.

, Rosen, director of the Drug Development Program at Ronald Reagan University of California, Los Angeles Medical Center, president of Premier Oncology, discussed the benefits of bevacizumab and how biosimilars could change the field.

OncLive: What is the cost and benefit of bevacizumab?

Rosen: Bevacizumab has been an essential component of mCRC therapy for several years. It really augments how well chemotherapy can work. Bevacizumab, like all biologics, is extraordinarily expensive. There's always a constant conversation of risk and benefit and cost and benefit. This comes into play when you're treating [a patient] with any drug. Expensive drugs are always going to be subject to much more attention on the part of the payer, as well as certain healthcare systems. Bevacizumab is an example of many drugs in that category.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication